AUS
NZ
UK
CA
USA
IND
Healthcare
Creo Medical Secures £12 Million to Fuel Growth and Target Break-Even
October 01, 2024 08:05 AM BST| By Team Kalkine MediaHighlights,Creo Medical Group PLC successfully raises £12 million through a share placement to support growth.,Additional stock offerings could generate up to £5 million, bringing total funding to £40 million.,Funds will facilitate increased producti...
FTSE 100 Live: London Shares Poised for Uptick Ahead of Key Economic Update
October 01, 2024 07:45 AM BST| By Team Kalkine MediaHighlights,Haleon PLC completes a share repurchase agreement with Pfizer Inc, totaling £230 million.,The transaction concludes Haleon’s £500 million share buyback program initiated in August.,Pfizer’s stake in Haleon is reduced from 22.6% to 15%.,Hal...
Haleon Acquires Shares as Pfizer Reduces Its Position
October 01, 2024 07:35 AM BST| By Team Kalkine MediaHighlights,Haleon PLC completes a significant share repurchase from Pfizer Inc.,The transaction concludes a £500 million share buyback program initiated in August.,Pfizer’s ownership stake in Haleon will decrease from 22.6% to 15%.,Haleon PLC,{LSE:HL...
Celadon Pharmaceuticals Announces CFO Jonathan Turner’s Departure
September 30, 2024 05:21 PM BST| By Team Kalkine MediaHighlights:,Celadon Pharmaceuticals announced CFO Jonathan Turner will step down from his position on 27 December.,The company has begun the search for a successor, with an update to follow once a new CFO is appointed.,Shares in Celadon Pharmaceutica...
Ondine Biomedical (LSE:OBI) records 101% jump in revenue in 1HFY24, shares on radar
September 30, 2024 08:20 AM BST| By Team Kalkine MediaOndine Biomedical Inc. (LSE:OBI),, a prominent provider of light-activated antimicrobial technology aimed at preventing and treating hospital infections, has reported robust operational results for the first half of 2024. The company highlights signi...
Avacta Group (LSE:AVCT) releases interim results, eyes NASDAQ listing
September 30, 2024 07:58 AM BST| By Team Kalkine MediaAvacta Group plc (LSE:AVCT), a life sciences company known for developing innovative oncology drugs and diagnostics, has released its unaudited interim results for the six months ending June 30, 2024. The company has made significant strides towards...
hVIVO Introduces hLAB Standalone Services at New Canary Wharf facility
September 30, 2024 07:46 AM BST| By Team Kalkine MediaHighlights,Launch of hLAB standalone services expands virology and immunology laboratory capabilities.,New Canary Wharf facility increases laboratory capacity, allowing for advanced research.,Introduction of a biobank and CL-3 facility enhances suppo...
ValiRx Reports Reduced Losses and Operational Milestones
September 27, 2024 04:55 PM BST| By Team Kalkine MediaHighlights:,Narrowed Losses:,ValiRx reported a comprehensive loss of £0.97 million, an improvement from the previous year’s loss.,Operational Milestones:,The company signed its first U.S. customer and expanded its Inaphaea Biobank to include advanced...
OptiBiotix Health Reports Revenue Decline for First Half of the Year
September 27, 2024 04:40 PM BST| By Team Kalkine MediaHighlights:,Revenue Decline:,OptiBiotix Health reported a 21.3% decrease in revenue, totaling £0.28 million for the first half of the year.,Strategic Focus:,The company is enhancing operational efficiency and expanding partnerships to improve market...
Totally Secures New Contracts to Enhance NHS Services
September 27, 2024 04:40 PM BST| By Team Kalkine MediaHighlights:,New Contracts Secured:,Totally plc has obtained a £5.0 million insourcing contract and a £1.1 million extension for its NHS 111 services.,Expansion Plans:,The contracts enhance Totally’s presence across the north of England, improving pat...
Roquefort Therapeutics' Innovative Cancer Approach Attracts Attention from Big Pharma and Private Equity
September 27, 2024 09:09 AM BST| By Team Kalkine MediaHighlights,Innovative Drug Development,: Roquefort Therapeutics is advancing first-in-class oncology drugs, focusing on high-growth therapeutic areas with the potential for lucrative partnerships.,Strategic Partnerships,: The company has signed its f...
Hemogenyx Pharmaceuticals Prepares for Phase I Trial
September 27, 2024 09:02 AM BST| By Team Kalkine MediaHighlights,Clinical Trial Advancement,: Hemogenyx Pharmaceuticals is nearing the launch of a Phase I trial for its lead asset, HEMO-CAR-T, aimed at treating acute myeloid leukemia (AML).,Strategic Partnerships,: The first patient will be treated at t...
PureTech Health Gains Approval for Schizophrenia Drug, Unlocking New Revenue Streams
September 27, 2024 08:16 AM BST| By Team Kalkine MediaHighlights:,FDA approval for KarXT (Cobenfy),: Schizophrenia treatment approval results in milestone payments and opens potential revenue streams.,Strategic royalty agreements,: PureTech to receive approximately 2% royalties on sales above €2 billion...
H&M Results Met with Tepid Market Reaction
September 26, 2024 03:44 PM BST| By Team Kalkine MediaHighlights,H&M reports a slight decline in revenue for the third quarter, prompting concerns from analysts.,EBIT margins significantly underperform expectations, raising doubts about profitability targets.,An additional trading update indicates a pro...
Graft Polymer Welcomes Dennis Purcell as New Chairman
September 26, 2024 03:38 PM BST| By Team Kalkine MediaGraft Polymer (UK) PLC (LSE:GPL) has appointed Dennis Purcell as the new chairman of its board. Purcell, co-founder and former managing partner of Aisling Capital, brings extensive experience in the healthcare and biopharmaceutical industries, having...
Synairgen Advances SNG001 Phase II Trial Plans for Severe Viral Lung Infections
September 26, 2024 03:38 PM BST| By Team Kalkine MediaHighlights:,SNG001 Trial Preparations,: Synairgen has completed the design for a phase II trial and optimised aerosol delivery for ventilator patients.,Funding Requirements,: Additional capital is needed to initiate the large-scale study, with update...
Incanthera PLC Expands Skin + CELL Skincare Launch Across Europe
September 26, 2024 03:28 PM BST| By Team Kalkine MediaHighlights:,Accelerated Launch,: Incanthera's Skin + CELL skincare range is rolling out across Europe faster than initially planned.,Boosted Financial Confidence,: The expansion supports the projection of revenues exceeding £10 million for the financ...
Arecor Therapeutics Highlights Progress and Ambitions in Interim Results
September 26, 2024 03:23 PM BST| By Team Kalkine MediaHighlights:,Promising Lead Asset,: Arecor’s AT278 fast-acting insulin outperforms current treatments in clinical trials.,Pipeline Expansion,: Plans to enter the GLP-1 market and partnership with Medtronic strengthen the company’s position.,Positive F...
Novacyt (LSE:NCYT) Strengthens Financials and Expands Diagnostic Offerings in First Half of 2024
September 26, 2024 07:33 AM BST| By Team Kalkine MediaNovacyt S.A. (EURONEXT GROWTH:ALNOV; LSE:NCYT), a leading international molecular diagnostics company, has reported its unaudited interim results for the six-month period ending June 30, 2024. The company demonstrated significant growth in key areas,...
Does Shield Therapeutics Soar Post Thrilling Phase III?
September 25, 2024 05:04 PM BST| By Team Kalkine MediaHighlights:,Share Price Rise,: Shield Therapeutics PLC shares increased following the announcement of promising Phase III trial results for its iron deficiency treatment, Accrufer.,Efficacy in Pediatrics,: Accrufer demonstrated significant effectiven...
